---
category: news
title: "Kiromic Announces FDA IND Submission First-In-Human, AI derived Off-The-Shelf IsoMesothelin Gamma Delta CAR T-cell Therapy, 30 Days Before the End of the Second Quarter"
excerpt: "Kiromic achieves key milestone for this first-in-human Phase 1 clinical trial with a target derived by Kiromicâ€™s AI platform. HOUSTON-- ( BUSINESS WIRE )--Kiromic Biopharma, Inc. (Nasdaq: KRBP), an immuno-oncology target discovery and gene-editing company with a proprietary artificial intelligence neural network platform (Diamond AI) that is used to develop novel oncology therapeutics,"
publishedDateTime: 2021-05-24T15:55:00Z
originalUrl: "https://www.businesswire.com/news/home/20210524005256/en/Kiromic-Announces-FDA-IND-Submission-First-In-Human-AI-derived-Off-The-Shelf-IsoMesothelin-Gamma-Delta-CAR-T-cell-Therapy-30-Days-Before-the-End-of-the-Second-Quarter"
webUrl: "https://www.businesswire.com/news/home/20210524005256/en/Kiromic-Announces-FDA-IND-Submission-First-In-Human-AI-derived-Off-The-Shelf-IsoMesothelin-Gamma-Delta-CAR-T-cell-Therapy-30-Days-Before-the-End-of-the-Second-Quarter"
type: article

provider:
  name: Business Wire
  domain: businesswire.com

topics:
  - AI in Healthcare
  - AI

secured: "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;O8UHkLZLHzcA7BqruE6YSQ=="
---

